Medios (ILM1) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
25 Nov, 2025Executive summary
Revenue increased by 6.2% year-over-year to €484.7 million in Q1 2025, driven by international business and the consolidation of the Ceban Group.
EBITDA pre rose 52.9% to €23.1 million, with margin improvement to 4.8% from 3.3% in Q1 2024.
Net income grew 60% year-over-year to €6.4 million, with EPS up 47.1% to €0.25.
CEO Matthias Gärtner to step down by end of 2025; COO Mi-Young Miehler will leave mid-2025 as part of executive board changes, with transition plans in place.
Strategic focus shifted towards commercial and business development, leveraging synergies from the Ceban acquisition and expansion in Advanced Therapies.
Financial highlights
Gross profit increased 80% to €49.8 million, with margin rising to 10.3% from 6.1% year-over-year.
Operating profit (EBIT) rose 88.5% to €12.3 million.
Operating cash flow at €3.6 million, impacted by net working capital effects and down from €43.4 million year-over-year.
Cash and cash equivalents at €89.2 million.
CapEx more than doubled to €1.2 million.
Outlook and guidance
Full-year 2025 guidance confirmed: revenue expected at approximately €2 billion (+6%), EBITDA pre at €96 million (+21.5%), with a margin of 4.8%.
Organic growth anticipated in the mid-single-digit percentage range, with full-year Ceban Group consolidation.
Estimated annual future free cash flow of €40–50 million; €30–40 million available for debt redemption.
Latest events from Medios
- Targeting €3.1bn revenue and €170m EBITDA by 2031, with compounding as the main growth driver.ILM1
CMD 2026 - Strong revenue growth and market leadership in European specialty pharma, with ongoing margin optimization.ILM1
Company presentation - Revenue up 8.4% but profitability declined; outlook lowered amid margin and regulatory pressures.ILM1
Q2 2026 - 2026 revenue outlook raised but earnings cut amid price and regulatory pressures; cost controls ongoing.ILM1
Investor update - Revenue up 8.9%, EBITDA pre margin down to 4.0%, guidance confirmed, and cannabis market entry.ILM1
Q1 2026 - Double-digit revenue and profit growth in 2025, with strong margin-focused 2026 outlook.ILM1
Q4 2025 - EBITDA pre up 48.8% and net income nearly doubled on strong segment and international growth.ILM1
Q2 2025 - Record Q3 and EBITDA pre growth driven by Ceban integration and margin expansion.ILM1
Q3 2024 - Ceban acquisition and PS growth drove 6.3% revenue and 7.3% EBITDA pre increase in H1 2024.ILM1
Q2 2024